About the offering
Drug therapy provides low to modest efficacy with high side effect rate and high cost. Antidepressants, anti-anxiety and sleep medications all have a high rate of side effects, and even in generic form can be very expensive - and the many doctor visits needed to manage medication are also costly. Behavioral therapy (psychotherapy or CBT) does not cause serious side effects but is expensive to administer and requires a very high level of patient engagement. FDA-Cleared wearable treatment - just 20 minutes per day. The Fisher Wallace Stimulator® comfortably stimulates the brain to produce neurochemicals such as serotonin, while modulating the brain’s default mode network and reducing cortisol, as demonstrated in published studies. The device has a 75% effectiveness rate and 1% side effect rate in clinical trials and practice - compared to the 38% side effect rate of SSRI medication. $23.3 Million lifetime revenue and profitable! Named as an INC 5000 fastest growing company, Fisher Wallace has demonstrated product-market fit by selling over 50,000 medical devices - prescribed by over 10,000 licensed healthcare providers in the United States.
FAQ
How much has Fisher Wallace raised?
Fisher Wallace has raised $1M of a $1.07M goal.
Where is Fisher Wallace's campaign listed?
The offering is listed on StartEngine, an SEC-registered Reg CF intermediary.
What are the terms of Fisher Wallace's raise?
Common Stock, $15M cap, $2.50/share.
When does Fisher Wallace's offering close?
The stated close date is Mar 9, 2020.